Table 4.
Pre-discharge (baseline) troponin I | |||
---|---|---|---|
Endpoint(12 months) | Subgroup | Adjusted HR (95% CI) | P for interaction |
ACM | CAD | 1.36 (0.99–1.87) | 0.737 |
Non-CAD | 1.05 (0.71 –1.58) | ||
DM | 1.35 (0.92–1.97) | 0.427 | |
Non-DM | 1.15 (0.82–1.61) | ||
CVM/HHF | CAD | 0.98 (0.78–1.24) | 0.052 |
Non-CAD | 1.29 (0.96–1.72) | ||
DM | 1.07 (0.82–1.40) | 0.862 | |
Non-DM | 1.11 (0.87–1.43) | ||
1-month troponin I | |||
ACM | CAD | 2.12 (1.47–3.07) | 0.009 |
Non-CAD | 0.96 (0.59–1.57) | ||
DM | 1.79 (1.16–2.77) | 0.456 | |
Non-DM | 1.43 (0.96–2.14) | ||
CVM/HHF | CAD | 1.41 (1.09–1.83) | 0.1 93 |
Non-CAD | 1.07 (0.76–1.51) | ||
DM | 1.31 (0.97–1.78) | 0.787 | |
Non-DM | 1.24 (0.93 –1.65) |
ACM, all-cause mortality; CAD, coronary artery disease; CI, confidence interval; CVM/HHF, cardiovascular mortality or hospitalization for heart failure; DM, diabetes mellitus; HR, hazard ratio.
Data represent interaction P values from multivariate analysis. Covariates included in the multivariate model: age, gender, race, geographic region, ischaemic heart failure aetiology, New York Heart Association class III/IV, ejection fraction, systolic blood pressure, heart rate, NT-proBNP level, serum sodium, blood urea nitrogen, serum creatinine, QRS duration, aliskiren randomization, past medical history (prior HHF, coronary artery disease, atrial fibrillation, diabetes, chronic obstructive pulmonary disease), and medications (ACEI/ARB, beta-blocker, mineralocorticoid receptor antagonist, digoxin, implantable cardioverter-defibrillator, cardiac resynchronization therapy).